• Chest · Mar 2014

    Heliox-Driven Vs. Air-Driven Nebulized Bronchodilator (BD) Therapy and Pulmonary Function Tests (PFT) in Patients With Obstructive Lung Diseases.

    • Mohamad El Khatib, Ghassan Jamaleddine, Nadim Kanj, Juliette Jibrail, Marwan Alawieh, Salah Zeineddine, Imad Bouakl, Ahmad Husari, Hassan Chami, and Pierre Boukhalil.
    • Chest. 2014 Mar 1;145(3 Suppl):462A.

    Session TitlePhysiology/PFTs/Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To compare the effect of heliox-driven (Helium 80%: Oxygen 20%) to air-driven (Nitrogen 79%; Oxygen 21%) BD therapy on PFTs in patients with different levels of severity of airway obstructions.Methods150 patients undergoing their first pre- and post-bronchodilator PFT measurements were included in the study. Pregnant women and morbidly obese patients were excluded. Each patient was studied on two consecutive days with random assignment to receive either air-driven nebulization of 2.5mg of albuterol sulfate on day one and heliox-driven nebulization of same drug on day two or vice versa. After baseline PFT on day one, each patient received the nebulized bronchodilator treatment for 10 minutes at a flow rate of 8L/min with the randomized driving gas for day one. Post bronchodilator PFT was repeated after 30 minutes. The next day, the exact protocol was performed except that the other driving gas was used to nebulize the drug. The patients and the staff conducting the PFTs were blinded to the driving gas. Patients were sub-grouped and analyzed according to their baseline FEV1 on day one: 100%>FEV1≥80%; 80%>FEV1>50%; FEV1≤50%. Changes from baseline in PFT variables were compared with heliox-driven versus air-driven bronchodilation therapy.ResultsThe percentages of patients who showed >12% increases in FEV1 with either heliox-driven or air-driven bronchodilation were not different in patients with 100%>FEV1≥80% (20% vs. 20%) and 80%>FEV1>50% (38% vs. 28%) but significantly greater in patients with FEV1≤50% (58% vs. 18%). Only in patients with FEV1≤50%, changes from baseline in FVC, FEV1, FEV1/FVC, FEF25-75%, FEFmax, FEF25%, FEF50%, and FEF75% were larger with heliox-driven versus air-driven bronchodilation.ConclusionsPFT variables improvements are more frequent and larger with heliox-driven compared to air-driven bronchodilator therapy only in patients with FEV1≤50%.Clinical ImplicationsIn patients with severe airway obstructions heliox-driven should replace air-driven bronchodilation for identifying patients who will exhibit positive response to bronchodilator therapy. Physicians should consider heliox-driven bronchodilator therapy when seeking improvements in PFT variables in patients with severe obstructive airway diseases.DisclosureThe following authors have nothing to disclose: Mohamad El Khatib, Ghassan Jamaleddine, Nadim Kanj, Juliette Jibrail, Marwan Alawieh, Salah Zeineddine, Imad BouAkl, Ahmad Husari, Hassan Chami, Pierre BouKhalilNo Product/Research Disclosure Information.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.